Press releases

RaySearch Laboratories AB to be listed on Stockholm Stock Exchange’s Attract40

Effective July 1, 2005, RaySearch Laboratories will be listed in the Attract40 segment of the Stockholm Stock Exchange’s O List. RaySearch develops and sells software for radiation therapy of cancer. The company was listed on the O List of the Stockholm Stock Exchange in November 2003 and, during the past six months, the market interest in RaySearch has been so extensive that the company now qualifies to join the Attract40 segment.

Johan Löf, President and CEO of RaySearch Laboratories AB, says: ”It is satisfying that the interest among investors is so great that RaySearch is to be listed on the Attract40. According to the Stockholm Stock Exchange, the aim of Attract40 is to highlight attractive O List companies for foreign investors and small-scale Swedish share investors. One of the criteria for joining the list is that the rate of turnover of shares during the most recent six-month period must be among the 40 highest on the Stockholm Stock Exchange O List.” Johan Löf continues: “In our most recent interim report, we stated that RaySearch has a stable financial base for expansive future development. The partnership with Nucletron means that our products will become available to a large number of new clinics throughout the world and, accordingly, the company will substantially increase its numbers of potential customers. Sales of the first product within the framework of this cooperation began in April. A month ago, we signed a letter of intent with our cooperative partner of many years, Philips, regarding establishment of a long-term licensing agreement for new products in adaptive radiotherapy, a therapy regarded as the next technology leap.” About RaySearch RaySearch develops and sells software for radiation therapy of cancer. The products are specially developed to optimize radiation therapy and the purpose is to adapt the radiation dose to the shape of the tumor, which allows high doses to be delivered to the tumor while minimizing the dose to surrounding healthy tissue. RaySearch, a spin-off from Karolinska Institutet, was formed in 2000. RaySearch has sold its product, RayOptimizer, to more than 800 hospitals around the world through a licensing agreement with Philips, enabling tens of thousands of patients to receive improved radiation therapy. RaySearch was listed on the Stockholm Stock Exchange O-list in November 2003. Sales of the products RayBiology and RayMachine began in 2004 and the partnership with Philips continues. RaySearch signed a licensing agreement with Nucletron in January 2004. The latter agreement made RaySearch's products available to a large number of new clinics worldwide and, consequently, increased the number of potential customers sharply. Delivery to clinics of the first product based on the partnership with Nucletron, OM-Optimizer, began in April 2005. RaySearch is based in Stockholm and currently has 28 employees. Company website: For further information, please contact: Johan Löf President and CEO, RaySearch Laboratories AB Tel: +46 (0)8 – 545 061 30